WO2011053003A3 - Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer - Google Patents

Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer Download PDF

Info

Publication number
WO2011053003A3
WO2011053003A3 PCT/KR2010/007456 KR2010007456W WO2011053003A3 WO 2011053003 A3 WO2011053003 A3 WO 2011053003A3 KR 2010007456 W KR2010007456 W KR 2010007456W WO 2011053003 A3 WO2011053003 A3 WO 2011053003A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyethyleneoxide
graft copolymer
gastric
sustained release
formulation containing
Prior art date
Application number
PCT/KR2010/007456
Other languages
French (fr)
Other versions
WO2011053003A2 (en
Inventor
Il Hwan Cho
Il Ki Hong
Kyung Min Shin
Da Won Oh
A Ra Ahn
Hyun Jung Noh
Hyun Ah Kang
Hong Chul Jin
Bo Hyun Sung
Original Assignee
Cj Cheiljedang Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corporation filed Critical Cj Cheiljedang Corporation
Publication of WO2011053003A2 publication Critical patent/WO2011053003A2/en
Publication of WO2011053003A3 publication Critical patent/WO2011053003A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a gastric-retentive sustained release formulation containing pregabalin or a pharmaceutically acceptable salts thereof, polyethyleneoxide, and polyvinylalcohol-polyethyleneglycol graft copolymer, in which a swelling property and floatability of matrix is improved by using a polyethyleneoxide and polyvinylalcohol-polyethyleneglycol graft copolymer, thereby controlling the release of the drug.
PCT/KR2010/007456 2009-10-28 2010-10-28 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer WO2011053003A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20090102539 2009-10-28
KR10-2009-0102539 2009-10-28
KR10-2010-0105414 2010-10-27
KR1020100105414A KR101317592B1 (en) 2009-10-28 2010-10-27 Gastric-retentive sustained release fomulation containing pregabalin and pva-peg graft copolymer

Publications (2)

Publication Number Publication Date
WO2011053003A2 WO2011053003A2 (en) 2011-05-05
WO2011053003A3 true WO2011053003A3 (en) 2011-09-22

Family

ID=43922835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007456 WO2011053003A2 (en) 2009-10-28 2010-10-28 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer

Country Status (2)

Country Link
KR (1) KR101317592B1 (en)
WO (1) WO2011053003A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
CN103702664B (en) * 2011-07-26 2016-10-19 柳韩洋行 By the slow releasing tablet containing Pregabalin of biphase controlled release system
KR101438546B1 (en) * 2011-08-26 2014-09-17 근화제약주식회사 Controlled-release formulations comprising pregabalin
KR101269829B1 (en) * 2012-04-27 2013-05-30 씨제이제일제당 (주) Sustained release preparation using gastric retentive drug delivery system
EP3099288A1 (en) * 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (en) * 2014-04-07 2021-02-26 영진약품 주식회사 Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof
CA3030105A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
KR102039345B1 (en) * 2017-02-01 2019-11-01 지엘팜텍주식회사 A high swellable sustained-release triple-layer tablet containing pregabalin
KR102039344B1 (en) * 2017-02-01 2019-11-01 지엘팜텍주식회사 An orally administered sustained-release triple-layer tablet containing pregabalin
CN111053749B (en) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 Pregabalin sustained-release composition and preparation method thereof
CN111741748B (en) * 2018-06-13 2022-09-23 北京泰德制药股份有限公司 Pregabalin sustained-release composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070269511A1 (en) * 2005-11-02 2007-11-22 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353196A1 (en) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form with a matrix influencing the delivery of a modulatory substance
US8454993B2 (en) 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070269511A1 (en) * 2005-11-02 2007-11-22 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin

Also Published As

Publication number Publication date
KR101317592B1 (en) 2013-10-15
KR20110046360A (en) 2011-05-04
WO2011053003A2 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2011049706A8 (en) Orally transformable tablets
WO2009063222A3 (en) Solid compositions
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2010054266A3 (en) Multiblock copolymers
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2008037716A3 (en) Pharmaceutical compositions comprising nilotinib or its salt
WO2010009140A3 (en) Methods, systems and devices for administration of chlorine dioxide
EP3272337A3 (en) Tablets
WO2008049657A3 (en) Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release
WO2009135593A3 (en) Solid pharmaceutical formulation with delayed release
WO2011104652A3 (en) Veterinary compositions
WO2012022919A3 (en) Nalbuphine-based formulations and uses thereof
WO2014106116A8 (en) Therapeutic compositions comprising antibodies
WO2010049449A3 (en) Novel salts of sunitinib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2010116382A3 (en) Stable pharmaceutical compositions of diclofenac
EP2241310A3 (en) Modified release formulations of emoxypine
WO2009023761A3 (en) Pharmaceutical compositions comprising ropinirole
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2011064797A3 (en) Controlled release pharmaceutical compositions of galantamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827087

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827087

Country of ref document: EP

Kind code of ref document: A2